EPIDEMIOLOGY OF ISOTRETINOIN EXPOSURE DURING PREGNANCY

被引:83
|
作者
DAI, WS [1 ]
LABRAICO, JM [1 ]
STERN, RS [1 ]
机构
[1] HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT DERMATOL,BOSTON,MA 02215
关键词
D O I
10.1016/0190-9622(92)70088-W
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Exposure to isotretinoin during pregnancy is associated with a high risk of major fetal malformations. Objective: Our purpose was to determine the reasons for and outcomes of in utero isotretinoin exposure. Methods: On the basis of 433 spontaneous reports, we describe the likely reasons these exposures occurred and the outcomes of these pregnancies. In our analysis of the outcomes of pregnancy, we separately consider the pregnancies known to us before their outcomes were determined as prospective cases. Results: Timing of conception in relation to initiation of therapy with isotretinoin was known for 396 women. Of these, 130 patients (33%) were already pregnant when they started isotretinoin. An additional 65 patients (16%) became pregnant in the first 3 weeks of isotretinoin use. Pregnancy outcomes were known on 409 pregnancies. Among these, 222 (54%) ended in elective abortion and 29 (7%) in spontaneous or missed abortion. Of 151 births, 72 (48%) were normal, 71 (47%) had congenital malformations, and 8 (5%) had abnormalities other than malformations. Of 94 prospectively ascertained pregnancies that ended in births, 28% had congenital malformations (95% confidence interval 19% to 37%). Exposure to isotretinoin during any time and for as little as one capsule within the first trimester have been associated with congenital malformations. Conclusion: The high proportion of exposures in already or recently pregnant women illustrates the importance of obtaining a negative pregnancy test before the initiation of isotretinoin therapy and of delaying the commencement of isotretinoin therapy until the onset of the next menstrual period. Furthermore, the importance of reliable contraceptive methods should be emphasized to patients when isotretinoin is prescribed. Young women seem to be at an especially high risk of pregnancy exposure to isotretinoin. There is a substantial risk of congenital malformation at all therapeutic doses of isotretinoin, even when the duration of exposure is brief.
引用
收藏
页码:599 / 606
页数:8
相关论文
共 50 条
  • [1] Epidemiology of Isotretinoin Exposure During Pregnancy
    Jonville-Bera, A. P.
    Elefant, E.
    Cissoko, H.
    Bensouda-Grimaldi, L.
    Autret-Leca, E.
    DRUG SAFETY, 2009, 32 (10) : 961 - 961
  • [2] Isotretinoin exposure during pregnancy
    Autret-Leca, E.
    Jais, C. Kreft
    Elefant, E.
    Cissoko, H.
    Darrouzain, F.
    Bensouda-Grimaldi, L.
    Attia, S.
    Jonville-Bera, A. P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 93 - 93
  • [3] Isotretinoin Exposure during Pregnancy Assessment of Spontaneous Reports in France
    Autret-Leca, Elisabeth
    Kreft-Jais, Carmen
    Elefant, Elisabeth
    Cissoko, Haware
    Darrouzain, Francois
    Grimaldi-Bensouda, Lamiae
    Attia, Sarah
    Jonville-Bera, Annie Pierre
    DRUG SAFETY, 2010, 33 (08) : 659 - 665
  • [4] Isotretinoin exposure during pregnancy: a population-based study in The Netherlands
    Zomerdijk, Ingeborg M.
    Ruiter, Rikje
    Houweling, Leanne M. A.
    Herings, Ron M. C.
    Sturkenboom, Miriam C. J. M.
    Straus, Sabine M. J. M.
    Stricker, Bruno H.
    BMJ OPEN, 2014, 4 (11):
  • [5] Exposure to Isotretinoin in Pregnancy: An Ongoing Problem
    Berlin, Maya
    Dinavitser, Natalia
    Gorelik, Einat
    Dil, Dorit Nahlieli
    Berkovitch, Mati
    BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2014, 100 (07) : 519 - 520
  • [6] Exposure to Isotretinoin during Pregnancy in France: 25 Years of Follow-up
    Rouzes, Agnes
    Jonville-Bera, Annie-Pierre
    THERAPIE, 2014, 69 (01): : 53 - 63
  • [7] Does topical isotretinoin exposure during pregnancy increase the risk of congenital malformations?
    Yilmaz, Ismail
    Kaplan, Yusuf Cem
    Karadas, Baris
    Temiz, Tijen Kaya
    Karaca, Semsettin
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2015, 49 (02): : 92 - 94
  • [8] Use of isotretinoin among girls and women of childbearing age and exposure during pregnancy
    Reinold, Jonas
    Kollhorst, Bianca
    Haug, Ulrike
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 244 - 244
  • [9] Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy
    Henry, David
    Dormuth, Colin
    Winquist, Brandace
    Carney, Greg
    Bugden, Shawn
    Teare, Gary
    Levesque, Linda E.
    Berard, Anick
    Paterson, J. Michael
    Platt, Robert W.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2016, 188 (10) : 723 - 730
  • [10] Drug exposure during pregnancy: advantages and limits of epidemiology for fisk assessment
    Robert-Gnansia, E
    THERAPIE, 2002, 57 (02): : 175 - 180